Recursion Pharmaceuticals Stock Forecast

Stock Price Forecast

According to 8 analysts polled by S&P Global, Recursion Pharmaceuticals stock has a consensus rating of "Hold" and an average price target of $6.64. The average 1-year stock price forecast is 110.13% higher than the current stock price, while the lowest is $3.00 (-5.06%) and the highest is $10 (+216.46%).

Price Target: $6.64 (+110.13%)

Analyst Consensus: Hold

Target	Low	Average	Median	High
Price	$3.00	$6.64	$6.00	$10
Change	-5.06%	+110.13%	+89.87%	+216.46%

Analyst Ratings

The average analyst rating for Recursion Pharmaceuticals stock is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.

Recommendation Trends

Rating	Dec '25	Jan '26	Feb '26	Mar '26	Apr '26	May '26
Strong Buy	1	1	1	1	1	1
Buy	2	2	2	2	2	2
Hold	5	5	5	5	5	5
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	8	8	8	8	8	8

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Sean Laaman Morgan Stanley	Morgan Stanley	Hold Maintains $5 → $5.5	Hold	Maintains	$5 → $5.5	+74.05%	May 14, 2026
Alec Stranahan Bank of America Securities	Bank of America Securities	Hold Maintains $6	Hold	Maintains	$6	+89.87%	May 13, 2026
Gil Blum Needham	Needham	Buy Reiterates $8	Buy	Reiterates	$8	+153.16%	May 7, 2026
Brendan Smith TD Cowen	TD Cowen	Hold Maintains n/a	Hold	Maintains	n/a	n/a	May 6, 2026
Priyanka Grover J.P. Morgan	J.P. Morgan	Buy Maintains $11 → $10	Buy	Maintains	$11 → $10	+216.46%	Apr 30, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

66.51M

from 74.68M

-10.94%

from 74.68M

Revenue Next Year

111.59M

from 66.51M

67.78%

from 66.51M

EPS This Year

-0.92

from -1.44

EPS Next Year

-0.88

from -0.92

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	10.18M	39.84M	44.58M	58.84M	74.68M	66.51M
Revenue Growth	156.89%	291.46%	11.88%	32.00%	26.92%	-10.94%
Gross Profit	-125.09M	-164.13M	-239.24M	-300.82M	-471.54M	66.51M
Gross Margin	-1,229.05%	-411.94%	-536.71%	-511.26%	-631.41%	100.00%
Operating Income	-182.78M	-245.73M	-350.06M	-479.00M	-648.13M	-507.78M
Net Income	-186.48M	-239.48M	-328.07M	-463.66M	-644.76M	-462.28M
EPS	-	-	-	-	-1.44	-0.92
Free Cash Flow	-121.93M	-105.41M	-187.37M	-194.33M	-208.52M	-193.00M
No. Analysts	-	-	-	-	-	8

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue	2026	2027	2028
High	86.5M
Avg	66.5M
Low	42.5M

Revenue Growth

Revenue Growth	2026	2027	2028
High	15.8%
Avg	-10.9%
Low	-43.1%

EPS Forecast

EPS	2026	2027	2028
High	-
Avg	-0.92
Low	-

EPS Growth

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-